Status quo for Japan conflict-of-interest

22 December 2008

The Study Committee on Conflict-of-Interest among members participating in committees under the Council on Pharmaceutical Affairs and Food Sanitation at Japan's Ministry of Health, Labor and Welfare has decided not to revise the current compliance agreement for conflict-of-interest. This was stated in a report, including a recommendation to the sub-committee on Pharmaceutical Affairs at the CPAFS, after having discussed the operational status of the deal or the results of a questionnaire survey among professors and universities, and hearings with representatives of both Japanese medical facilities and drug manufacturers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight